{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:22:11Z","timestamp":1772166131312,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      relapses due to dormant liver hypnozoites can be prevented with primaquine. However, the dose must be adjusted in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. In French Guiana, assessment of G6PD activity is typically delayed until day (D)14 to avoid the risk if misclassification. This study assessed the kinetics of G6PD activity throughout\n                      <jats:italic>P. vivax<\/jats:italic>\n                      infection to inform the timing of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      For this retrospective monocentric study, data on G6PD activity between D1 and D28 after treatment initiation with chloroquine or artemisinin-based combination therapy were collected for patients followed at Cayenne Hospital, French Guiana, between January 2018 and December 2020. Patients were divided into three groups based on the number of available G6PD activity assessments: (i) at least two measurements during the\n                      <jats:italic>P. vivax<\/jats:italic>\n                      malaria infection; (ii) two measurements: one during the current infection and one previously; (iii) only one measurement during the malaria infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 210 patients were included (80, 20 and 110 in groups 1, 2 and 3, respectively). Data from group 1 showed that G6PD activity remained stable in each patient over time (D1, D3, D7, D14, D21, D28). None of the patients with normal G6PD activity during the initial phase (D1\u2013D3) of the malaria episode (n\u2009=\u200944) was categorized as G6PD-deficient at D14. Patients with G6PD activity\u2009&lt;\u200980% at D1 or D3 showed normal activity at D14. Sex and reticulocyte count were statistically associated with G6PD activity variation. In the whole sample (n\u2009=\u2009210), no patient had severe G6PD deficiency (&lt;\u200910%) and only three between 10 and 30%, giving a G6PD deficiency prevalence of 1.4%. Among the 100 patients from group 1 and 2, 30 patients (26.5%) were lost to follow-up before primaquine initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In patients treated for\n                      <jats:italic>P. vivax<\/jats:italic>\n                      infection, G6PD activity did not vary over time. Therefore, G6PD activity on D1 instead of D14 could be used for primaquine dose-adjustment. This could allow earlier radical treatment with primaquine, that could have a public health impact by decreasing early recurrences and patients lost to follow-up before primaquine initiation. This hypothesis needs to be confirmed in larger prospective studies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-024-04973-4","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T02:41:12Z","timestamp":1715222472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity during Plasmodium vivax infection: implications for early radical malaria treatment"],"prefix":"10.1186","volume":"23","author":[{"given":"Laureen","family":"Dahuron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juste","family":"Goungounga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustapha","family":"Drame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maylis","family":"Douine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Nacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9o","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Mosnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Musset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Fouillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Djossou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Epelboin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"4973_CR1","volume-title":"World malaria report 2022","author":"WHO","year":"2022","unstructured":"WHO. World malaria report 2022. Geneva: World Health Organization; 2022."},{"key":"4973_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"MD Cappellini","year":"2008","unstructured":"Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64\u201374.","journal-title":"Lancet"},{"key":"4973_CR3","volume-title":"Guidelines for malaria","author":"WHO","year":"2023","unstructured":"WHO. Guidelines for malaria. Geneva: World Health Organization; 2023."},{"key":"4973_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.medmal.2019.07.011","volume":"50","author":"L Epelboin","year":"2020","unstructured":"Epelboin L, Rapp C, Faucher JF, M\u00e9cha\u00ef F, Bottieau E, Matheron S, et al. Management and treatment of uncomplicated imported malaria in adults. Update of the French malaria clinical guidelines. Med Mal Infect. 2020;50:194\u2013212.","journal-title":"Med Mal Infect"},{"key":"4973_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/ijms17122069","volume":"17","author":"S G\u00f3mez-Manzo","year":"2016","unstructured":"G\u00f3mez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, Serrano-Posada H, Ortega-Cuellar D, Gonz\u00e1lez-Valdez A, et al. Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the World. Int J Mol Sci. 2016;17:2069.","journal-title":"Int J Mol Sci"},{"key":"4973_CR6","doi-asserted-by":"publisher","first-page":"12691","DOI":"10.3390\/ijms241612691","volume":"24","author":"B Hern\u00e1ndez-Ochoa","year":"2023","unstructured":"Hern\u00e1ndez-Ochoa B, Ortega-Cuellar D, Gonz\u00e1lez-Valdez A, Mart\u00ednez-Rosas V, Morales-Luna L, Rojas-Alarc\u00f3n MA, et al. An overall view of the functional and structural characterization of glucose-6-phosphate dehydrogenase variants in the Mexican population. Int J Mol Sci. 2023;24:12691.","journal-title":"Int J Mol Sci"},{"key":"4973_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12936-018-2564-2","volume":"17","author":"S Avalos","year":"2018","unstructured":"Avalos S, Mejia RE, Banegas E, Salinas C, Gutierrez L, Fajardo M, et al. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients. Malar J. 2018;17:415.","journal-title":"Malar J"},{"key":"4973_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-12-418","volume":"12","author":"RE Howes","year":"2013","unstructured":"Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418.","journal-title":"Malar J"},{"key":"4973_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD Deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9: e1001339.","journal-title":"PLoS Med"},{"key":"4973_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12936-016-1365-8","volume":"15","author":"F Petit","year":"2016","unstructured":"Petit F, Bailly P, Chiaroni J, Mazi\u00e8res S. Sub-Saharan red cell antigen phenotypes and glucose-6-phosphate dehydrogenase deficiency variants in French Guiana. Malar J. 2016;15:310.","journal-title":"Malar J"},{"key":"4973_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4269\/ajtmh.19-0378","volume":"102","author":"E Mosnier","year":"2020","unstructured":"Mosnier E, Roux E, Cropet C, Lazrek Y, Moriceau O, Gaillet M, et al. Prevalence of Plasmodium spp. in the Amazonian border context (French Guiana\u2013Brazil): associated factors and spatial distribution. Am J Trop Med Hyg. 2020;102:130\u201341.","journal-title":"Am J Trop Med Hyg"},{"key":"4973_CR12","unstructured":"HCSP 2018. Avis HCSP 2018 relatif aux modalit\u00e9s d\u2019utilisation de la primaquine dans le traitement radical du paludisme \u00e0 Plasmodium vivax et Plasmodium ovale en France. [Internet]. Paris: Haut Conseil de la Sant\u00e9 Publique; 2018 mai [cited 14 Nov 2019]. Available on: https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=670"},{"key":"4973_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.23061","volume":"6","author":"J Watson","year":"2017","unstructured":"Watson J, Taylor WR, Menard D, Kheng S, White NJ. Modelling primaquine-induced haemolysis in G6PD deficiency. Elife. 2017;6: e23061.","journal-title":"Elife"},{"key":"4973_CR14","first-page":"373","volume":"30","author":"L Luzzatto","year":"2016","unstructured":"Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. 2016;30:373\u201393.","journal-title":"Blood"},{"key":"4973_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009690","volume":"15","author":"WRJ Taylor","year":"2021","unstructured":"Taylor WRJ, Kim S, Kheng S, Muth S, Tor P, Christophel E, et al. Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria. PLoS Negl Trop Dis. 2021;15: e0009690.","journal-title":"PLoS Negl Trop Dis"},{"key":"4973_CR16","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1073\/pnas.75.4.1979","volume":"75","author":"A Morelli","year":"1978","unstructured":"Morelli A, Benatti U, Gaetani GF, Flora AD. Biochemical mechanisms of glucose-6-phosphate dehydrogenase deficiency. Proc Natl Acad Sci USA. 1978;75:1979\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4973_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1420-9101.1999.00012.x","volume":"12","author":"SV Dongen","year":"1999","unstructured":"Dongen SV, Molenberghs, Matthysen. The statistical analysis of fluctuating asymmetry: REML estimation of a mixed regression model. J Evol Biol. 1999;12:94\u2013102.","journal-title":"J Evol Biol"},{"key":"4973_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040066","volume":"4","author":"A Guindo","year":"2007","unstructured":"Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007;4: e66.","journal-title":"PLoS Med"},{"key":"4973_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1051\/medsci\/2009256-7622","volume":"25","author":"S Picot","year":"2009","unstructured":"Picot S, Bienvenu AL. Plasmodium vivax sera-t-il un autre tueur en s\u00e9rie\u202f? Med Sci (Paris). 2009;25:622\u20136.","journal-title":"Med Sci (Paris)"},{"key":"4973_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/trstmh\/trt015","volume":"107","author":"MS Santana","year":"2013","unstructured":"Santana MS, Monteiro WM, Siqueira AM, Costa MF, Sampaio V, Lacerda MV, et al. Glucose-6-phosphate dehydrogenase deficient variants are associated with reduced susceptibility to malaria in the Brazilian Amazon. Trans R Soc Trop Med Hyg. 2013;107:301\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4973_CR21","doi-asserted-by":"publisher","first-page":"45963","DOI":"10.1038\/srep45963","volume":"7","author":"EC Mbanefo","year":"2017","unstructured":"Mbanefo EC, Ahmed AM, Titouna A, Elmaraezy A, Trang NTH, Phuoc Long N, et al. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Sci Rep. 2017;7:45963.","journal-title":"Sci Rep"},{"key":"4973_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4269\/ajtmh.2007.77.779","volume":"77","author":"S Duparc","year":"2007","unstructured":"Duparc S, Beutler E. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779\u201389.","journal-title":"Am J Trop Med Hyg"},{"key":"4973_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010406","volume":"16","author":"B Ley","year":"2022","unstructured":"Ley B, Alam MS, Satyagraha AW, Phru CS, Thriemer K, Tadesse D, et al. Variation in glucose-6-phosphate dehydrogenase activity following acute malaria. PLoS Negl Trop Dis. 2022;16: e0010406.","journal-title":"PLoS Negl Trop Dis"},{"key":"4973_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003576","volume":"18","author":"B Ley","year":"2021","unstructured":"Ley B, Alam MS, Kibria MG, Marfurt J, Phru CS, Ami JQ, et al. Glucose-6-phosphate dehydrogenase activity in individuals with and without malaria: analysis of clinical trial, cross-sectional and case\u2013control data from Bangladesh. PLoS Med. 2021;18: e1003576.","journal-title":"PLoS Med"},{"key":"4973_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2141.1976.tb00964.x","volume":"32","author":"F Brok-Simoni","year":"1976","unstructured":"Brok-Simoni F, Ashkenazi YE, Ramot B, Holtzman F. The diurnal rhythm of enzymes in human red cells. Br J Haematol. 1976;32:601\u20137.","journal-title":"Br J Haematol"},{"key":"4973_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, V\u00e9lez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229\u201341.","journal-title":"N Engl J Med"},{"key":"4973_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/IDR.S135897","volume":"11","author":"MS Mac Donald-Ottevanger","year":"2017","unstructured":"Mac Donald-Ottevanger MS, Adhin M, Jitan J, Bretas G, Vreden S. Primaquine double dose for 7 days is inferior to single-dose treatment for 14 days in preventing Plasmodium vivax recurrent episodes in Suriname. Infect Drug Resist. 2017;11:3\u20138.","journal-title":"Infect Drug Resist"},{"key":"4973_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3329\/jhpn.v27i1.3313","volume":"27","author":"N Khantikul","year":"2009","unstructured":"Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MSB, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in Northern Thailand. J Health Popul Nutr. 2009;27:4\u201313.","journal-title":"J Health Popul Nutr"},{"key":"4973_CR29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4103\/ijmr.IJMR_1167_19","volume":"154","author":"J Sharma","year":"2021","unstructured":"Sharma J, Gautam CS, Singh H, Singh J. Tafenoquine for Plasmodium vivax malaria: concerns regarding efficacy & safety. Indian J Med Res. 2021;154:797\u2013805.","journal-title":"Indian J Med Res"},{"key":"4973_CR30","unstructured":"AMAP\u00c1 GDED. Mal\u00e1ria: Governo Federal reconhece situa\u00e7\u00e3o de emerg\u00eancia em sete munic\u00edpios do Amap\u00e1 [Internet]. [cited 28 Feb 2024]. Available on: https:\/\/www.portal.ap.gov.br\/noticia\/0801\/malaria-governo-federal-reconhece-situacao-de-emergencia-em-sete-municipios-do-amapa"},{"key":"4973_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1475-2875-12-367","volume":"12","author":"M Nacher","year":"2013","unstructured":"Nacher M, Stefani A, Basurko C, Lemonnier D, Djossou F, Demar M, et al. The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana. Malar J. 2013;12:367.","journal-title":"Malar J"},{"key":"4973_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009720","volume":"15","author":"MM Ali Albsheer","year":"2021","unstructured":"Ali Albsheer MM, Lover AA, Eltom SB, Omereltinai L, Mohamed N, Muneer MS, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency (G6PDd), CareStart qualitative rapid diagnostic test performance, and genetic variants in two malaria-endemic areas in Sudan. PLoS Negl Trop Dis. 2021;15: e0009720.","journal-title":"PLoS Negl Trop Dis"},{"key":"4973_CR33","doi-asserted-by":"publisher","DOI":"10.2196\/29856","volume":"6","author":"Y Lambert","year":"2022","unstructured":"Lambert Y, Galindo M, Su\u00e1rez-Mutis M, Mutricy L, Sanna A, Garancher L, et al. Tailoring mobile data collection for intervention research in a challenging context: development and implementation in the Malakit study. JMIR Form Res. 2022;6: e29856.","journal-title":"JMIR Form Res"},{"key":"4973_CR34","first-page":"301","volume":"46","author":"AS Alving","year":"1955","unstructured":"Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955;46:301\u20136.","journal-title":"J Lab Clin Med"},{"key":"4973_CR35","volume":"10","author":"GN Galappaththy","year":"2013","unstructured":"Galappaththy GN, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev. 2013;10: CD004389.","journal-title":"Cochrane Database Syst Rev"},{"key":"4973_CR36","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1128\/AAC.02794-13","volume":"58","author":"S Pukrittayakamee","year":"2014","unstructured":"Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother. 2014;58:3354\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"4973_CR37","doi-asserted-by":"publisher","first-page":"e01965","DOI":"10.1128\/AAC.01965-18","volume":"63","author":"S Ladeia-Andrade","year":"2019","unstructured":"Ladeia-Andrade S, Menezes MJ, de Sousa TN, Silvino ACR, de Carvalho JF, Salla LC, et al. Monitoring the efficacy of chloroquine-primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil. Antimicrob Agents Chemother. 2019;63:e01965-e2018.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-04973-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-04973-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-04973-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T02:42:49Z","timestamp":1715222569000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-04973-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4973"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-04973-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3449547\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"15 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no competing interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}